Clinical Trial Detail

NCT ID NCT03775265
Title Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Atezolizumab + Cisplatin + Mitomycin C

Fluorouracil + Mitomycin C

Atezolizumab + Gemcitabine + Mitomycin C

Gemcitabine + Mitomycin C

Atezolizumab + Fluorouracil + Mitomycin C

Cisplatin + Mitomycin C

Age Groups: adult senior

No variant requirements are available.